{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:26:51Z","timestamp":1793600811202,"version":"4.5.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["HT94252410593"],"award-info":[{"award-number":["HT94252410593"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jid.2026.03.036","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T11:08:06Z","timestamp":1780139286000},"page":"2385-2395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Uveal melanoma: A review of current treatment limitations and the emerging therapeutic potential of natural killer cells"],"prefix":"10.1016","volume":"146","author":[{"given":"Revu V.L.","family":"Narayana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbigail L.","family":"Lanier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra","family":"Wajapeyee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5108-5962","authenticated-orcid":false,"given":"Romi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2026.03.036_bib1","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.molimm.2013.11.018","article-title":"Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease","volume":"58","author":"Achberger","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib3","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1167\/iovs.02-1147","article-title":"Reduction of liver metastasis of intraocular melanoma by interferon-beta gene transfer","volume":"44","author":"Alizadeh","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jid.2026.03.036_bib4","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jid.2026.03.036_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","article-title":"Human NK cell education by inhibitory receptors for MHC class I","volume":"25","author":"Anfossi","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2026.03.036_bib6","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/ceo.14214","article-title":"Current management of uveal melanoma: a review","volume":"51","author":"Bai","year":"2023","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jid.2026.03.036_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1146\/annurev.genom.7.080505.115726","article-title":"The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense","volume":"7","author":"Bashirova","year":"2006","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.jid.2026.03.036_bib8","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3389\/fonc.2019.01145","article-title":"Immunobiology of uveal melanoma: state of the art and therapeutic targets","volume":"9","author":"Basile","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2026.03.036_bib9","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-human phase I study of the oral inhibitor of indoleamine 2,3-Dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2026.03.036_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5802\/crbiol.63","article-title":"Cutaneous and uveal melanoma: two different cancers in therapeutic needs","volume":"344","author":"Bertolotto","year":"2021","journal-title":"C R Biol"},{"key":"10.1016\/j.jid.2026.03.036_bib11","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1055\/s-2007-963788","article-title":"Potenzieller endogener, immunologischer Schutzmechanismus uvealer Melanome durch Indoleamine 2,3-Dioxygenase [Potential endogenous immunological self-protection of uveal melanoma by indoleamine 2,3-dioxygenase]","volume":"225","author":"Beutelspacher","year":"2008","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.jid.2026.03.036_bib12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ijc.2910340321","article-title":"Inhibition of experimentally-induced murine metastases by recombinant alpha interferon: correlation between the modulatory effect of interferon treatment on natural killer cell activity and inhibition of metastases","volume":"34","author":"Brunda","year":"1984","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2026.03.036_bib13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cam4.133","article-title":"Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives","volume":"2","author":"Buder","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.jid.2026.03.036_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2102718118","article-title":"EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner","volume":"118","author":"Bugide","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jid.2026.03.036_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.trecan.2018.06.004","article-title":"Epigenetic mechanisms dictating eradication of cancer by natural killer cells","volume":"4","author":"Bugide","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jid.2026.03.036_bib16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcancer.2020.05.003","article-title":"Uveal melanoma pathobiology: metastasis to the liver","volume":"71","author":"Bustamante","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jid.2026.03.036_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2567.2010.03398.x","article-title":"Structure\/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations","volume":"132","author":"Campbell","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.jid.2026.03.036_bib18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jid.2026.03.036_bib19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41389-021-00339-6","article-title":"Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis","volume":"10","author":"Chava","year":"2021","journal-title":"Oncogenesis"},{"key":"10.1016\/j.jid.2026.03.036_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s44321-025-00357-6","article-title":"Loss of EHMT2 enhances NK cell-driven anti-tumor immunity through TGF-beta1 suppression","volume":"18","author":"Chava","year":"2026","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jid.2026.03.036_bib21","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.exer.2007.07.014","article-title":"Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion","volume":"85","author":"Chen","year":"2007","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jid.2026.03.036_bib22","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1167\/iovs.12-10977","article-title":"MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma","volume":"54","author":"Chen","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jid.2026.03.036_bib23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1167\/iovs.10-5272","article-title":"Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma","volume":"52","author":"Chen","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jid.2026.03.036_bib24","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.3389\/fimmu.2019.02078","article-title":"Human NK cell development: one road or many?","volume":"10","author":"Cichocki","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib26","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/eye.2012.255","article-title":"Molecular pathology of uveal melanoma","volume":"27","author":"Coupland","year":"2013","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jid.2026.03.036_bib27","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3390\/cells10071777","article-title":"KIR receptors as key regulators of NK cells activity in health and disease","volume":"10","author":"D\u0119bska-Zielkowska","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jid.2026.03.036_bib28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaophthalmol.2016.0903","article-title":"Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes","volume":"134","author":"Decatur","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jid.2026.03.036_bib29","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1182\/blood-2006-03-006700","article-title":"The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function","volume":"108","author":"Della Chiesa","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jid.2026.03.036_bib30","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1002\/cncr.34927","article-title":"Determinants of overall survival in patients with metastatic uveal melanoma","volume":"129","author":"Demkowicz","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.jid.2026.03.036_bib31","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.4049\/jimmunol.177.5.3100","article-title":"Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells","volume":"177","author":"Derr\u00e9","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib32","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archopht.118.8.1085","article-title":"Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma: a preliminary study","volume":"118","author":"Dithmar","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jid.2026.03.036_bib33","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.3390\/cancers13164129","article-title":"NK cell therapy: a rising star in cancer treatment","volume":"13","author":"Du","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2026.03.036_bib34","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/1097-0029(20010215)52:4<396::AID-JEMT1024>3.0.CO;2-V","article-title":"TGF-beta in uveal melanoma","volume":"52","author":"Esser","year":"2001","journal-title":"Microsc Res Tech"},{"key":"10.1016\/j.jid.2026.03.036_bib35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jid.2026.03.036_bib36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2004.10.016","article-title":"Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2026.03.036_bib37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-065X.2006.00445.x","article-title":"The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression","volume":"214","author":"Ghiringhelli","year":"2006","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jid.2026.03.036_bib38","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2006-04-020198","article-title":"Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells","volume":"108","author":"Grzywacz","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jid.2026.03.036_bib39","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1016\/j.cell.2018.11.048","article-title":"NKG2A, a new kid on the immune checkpoint block","volume":"175","author":"Haanen","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jid.2026.03.036_bib40","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.4049\/jimmunol.180.6.3766","article-title":"Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes","volume":"180","author":"Hallermalm","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib41","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jid.2026.03.036_bib42","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-year overall survival with tebentafusp in metastatic uveal melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.03.036_bib43","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1167\/iovs.04-0599","article-title":"Expression and possible function of IL-2 and IL-15 receptors on human uveal melanoma cells","volume":"45","author":"He","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jid.2026.03.036_bib44","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1002\/ijc.32951","article-title":"Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer","volume":"147","author":"Hellmann","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2026.03.036_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fimmu.2018.00151","article-title":"The role of Indoleamine-2,3-Dioxygenase in cancer development, diagnostics, and therapy","volume":"9","author":"Horny\u00e1k","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib46","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1167\/iovs.18-26477","article-title":"The interplay of MicroRNA-34a, LGR4, EMT-associated factors, and MMP2 in regulating uveal melanoma cells","volume":"60","author":"Hou","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jid.2026.03.036_bib47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1084\/jem.20082013","article-title":"IL-15 trans-presentation promotes human NK cell development and differentiation in vivo","volume":"206","author":"Huntington","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.jid.2026.03.036_bib48","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0198-8859(02)00389-0","article-title":"HLA expression in uveal melanoma: there is no rule without some exception","volume":"63","author":"Jager","year":"2002","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2026.03.036_bib50","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.3390\/cancers12123694","article-title":"Role of natural killer cells in uveal melanoma","volume":"12","author":"Javed","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2026.03.036_bib51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4155\/fmc.14.151","article-title":"Research progress of indoleamine 2,3-dioxygenase inhibitors","volume":"7","author":"Jiang","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.jid.2026.03.036_bib52","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10585-016-9815-9","article-title":"Expression of natural killer cell regulatory microRNA by uveal melanoma cancer stem cells","volume":"33","author":"Joshi","year":"2016","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.jid.2026.03.036_bib53","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jid.2026.03.036_bib54","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jid.2026.03.036_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1456631","article-title":"Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment","volume":"14","author":"Kumar","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2026.03.036_bib56","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/imm.12921","article-title":"Natural killer cell cytotoxicity and its regulation by inhibitory receptors","volume":"154","author":"Kumar","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.jid.2026.03.036_bib57","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1538-7445.AM2019-2319","article-title":"Accumulation and anti-tumor effect of chimeric antigen receptor (CAR) NK cells in metastatic uveal melanoma","volume":"79","author":"Lam","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2026.03.036_bib58","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbmt.2014.01.006","article-title":"Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells","volume":"20","author":"Leong","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jid.2026.03.036_bib59","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.18632\/oncotarget.2923","article-title":"MicroRNA dysregulation in uveal melanoma: a new player enters the game","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jid.2026.03.036_bib60","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.03.036_bib61","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1167\/iovs.08-2733","article-title":"Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients","volume":"50","author":"Maat","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jid.2026.03.036_bib62","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4049\/jimmunol.165.2.703","article-title":"Secondary V(D)J rearrangements and B cell receptor-mediated down-regulation of recombination activating gene-2 expression in a murine B cell line","volume":"165","author":"Ma\u00ebs","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib63","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ng.2674","article-title":"Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3","volume":"45","author":"Martin","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2026.03.036_bib64","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.3390\/cells11193147","article-title":"Next generation immuno-oncology strategies: unleashing NK cells activity","volume":"11","author":"Mendoza-Valderrey","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jid.2026.03.036_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2021.101501","article-title":"Cytokines and signaling pathways involved in differentiation potential of hematopoietic stem cells towards natural killer cells","volume":"70","author":"Montazersaheb","year":"2021","journal-title":"Tissue Cell"},{"key":"10.1016\/j.jid.2026.03.036_bib66","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jid.2026.03.036_bib67","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1002\/cncr.24999","article-title":"Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma","volume":"116","author":"Mougiakakos","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jid.2026.03.036_bib68","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jid.2026.03.036_bib69","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1186\/s12885-023-10727-3","article-title":"Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307\/KEYNOTE-672 study","volume":"23","author":"Necchi","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jid.2026.03.036_bib70","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.preteyeres.2009.06.002","article-title":"Immune escape mechanisms of intraocular tumors","volume":"28","author":"Niederkorn","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jid.2026.03.036_bib71","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","article-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma","volume":"12","author":"Ny","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2026.03.036_bib72","doi-asserted-by":"crossref","first-page":"172","DOI":"10.21037\/atm.2016.05.04","article-title":"Uveal melanoma as a target for immune-therapy","volume":"4","author":"Oliva","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jid.2026.03.036_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103623","article-title":"A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial)","volume":"9","author":"Olofsson Bagge","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jid.2026.03.036_bib74","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1101\/gad.296962.117","article-title":"Focus on cutaneous and uveal melanoma specificities","volume":"31","author":"Pandiani","year":"2017","journal-title":"Genes Dev"},{"key":"10.1016\/j.jid.2026.03.036_bib75","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/icb.2010.78","article-title":"Activating and inhibitory receptors of natural killer cells","volume":"89","author":"Pegram","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jid.2026.03.036_bib76","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, Phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jid.2026.03.036_bib77","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.annonc.2023.11.013","article-title":"Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis","volume":"35","author":"Piulats","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jid.2026.03.036_bib78","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jid.2026.03.036_bib79","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.3390\/ijms24119521","article-title":"NK cells in cancer: mechanisms of dysfunction and therapeutic potential","volume":"24","author":"Portale","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2026.03.036_bib80","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.cmet.2021.03.023","article-title":"Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment","volume":"33","author":"Poznanski","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.jid.2026.03.036_bib81","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0140-6736(96)90736-9","article-title":"Prognostic implications of monosomy 3 in uveal melanoma","volume":"347","author":"Prescher","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2026.03.036_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101041","article-title":"Metastatic uveal melanoma: the final frontier","volume":"90","author":"Rantala","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jid.2026.03.036_bib83","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.3390\/cancers12092557","article-title":"Treatment of metastatic uveal melanoma: systematic review","volume":"12","author":"Rodriguez-Vidal","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2026.03.036_bib84","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2026.03.036_bib85","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3389\/fphar.2016.00424","article-title":"Increased levels of miRNA-146a in serum and histologic samples of patients with uveal melanoma","volume":"7","author":"Russo","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jid.2026.03.036_bib86","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbmt.2020.09.030","article-title":"NK cell adoptive immunotherapy of cancer: evaluating recognition strategies and overcoming limitations","volume":"27","author":"Sanchez","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jid.2026.03.036_bib87","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.survophthal.2004.04.009","article-title":"Sunlight exposure and pathogenesis of uveal melanoma","volume":"49","author":"Singh","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jid.2026.03.036_bib88","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00262-020-02773-8","article-title":"Prognostic significance of PD-1\/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters","volume":"70","author":"Singh","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jid.2026.03.036_bib89","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/(SICI)1098-2264(199705)19:1<22::AID-GCC4>3.0.CO;2-2","article-title":"Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis","volume":"19","author":"Sisley","year":"1997","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jid.2026.03.036_bib90","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib91","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3390\/cancers11081132","article-title":"HLA expression in uveal melanoma: an indicator of malignancy and a modifiable immunological target","volume":"11","author":"Souri","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2026.03.036_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1356666","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity","volume":"15","author":"Stenger","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib93","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/bjc.2012.54","article-title":"Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study","volume":"106","author":"Thomas","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jid.2026.03.036_bib94","doi-asserted-by":"crossref","first-page":"8923","DOI":"10.1038\/s41598-021-88390-6","article-title":"Estimation of the timing of BAP1 mutation in uveal melanoma progression","volume":"11","author":"Uner","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jid.2026.03.036_bib95","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bjc.2017.259","article-title":"GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi","volume":"117","author":"Vader","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jid.2026.03.036_bib96","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1167\/iovs.11-8697","article-title":"Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis","volume":"53","author":"van den Bosch","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jid.2026.03.036_bib97","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","article-title":"Monalizumab: inhibiting the novel immune checkpoint NKG2A","volume":"7","author":"van Hall","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jid.2026.03.036_bib98","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/ijms22010336","article-title":"Genetics of ocular melanoma: insights into genetics, inheritance and testing","volume":"22","author":"van Poppelen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2026.03.036_bib99","doi-asserted-by":"crossref","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci Signal"},{"key":"10.1016\/j.jid.2026.03.036_bib100","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib101","first-page":"1258","article-title":"Role of microRNA-21 in uveal melanoma cell invasion and metastasis by regulating p53 and its downstream protein","volume":"11","author":"Wang","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jid.2026.03.036_bib102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1358\/dot.2023.59.3.3542417","article-title":"Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma","volume":"59","author":"Wang","year":"2023","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.jid.2026.03.036_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.961517","article-title":"Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases","volume":"12","author":"Wei","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2026.03.036_bib104","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2026.03.036_bib105","article-title":"Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2","volume":"7","author":"Yan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2026.03.036_bib106","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1167\/iovs.08-2681","article-title":"MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met","volume":"2009","author":"Yan","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jid.2026.03.036_bib107","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00018-020-03612-w","article-title":"Emerging roles of microRNAs and their implications in uveal melanoma","volume":"78","author":"Yang","year":"2021","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.jid.2026.03.036_bib108","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1167\/iovs.03-1331","article-title":"Interferon alpha 2b decreases hepatic micrometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells","volume":"45","author":"Yang","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jid.2026.03.036_bib109","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.4049\/jimmunol.1701461","article-title":"Canonical TGF-\u03b2 signaling pathway represses human NK cell metabolism","volume":"200","author":"Zaiatz-Bittencourt","year":"2018","journal-title":"J Immunol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X2601033X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X2601033X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:33:20Z","timestamp":1793597600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X2601033X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":109,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0022202X2601033X"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2026.03.036","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uveal melanoma: A review of current treatment limitations and the emerging therapeutic potential of natural killer cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2026.03.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}